The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
Open accessAbstract
OBJECTIVES: To measure the rate of progression in striatal [18F]dopa metabolism in a large group (n=32) of patients with Parkinson's disease, to estimate the average duration of preclinical period, and to examine the influence of the PET method on the assessment of rate of progression and preclinical period. METHODS: Thirty two patients with Parkinson's disease (mean age 58 (SD 13) years, mean duration 39 (SD 33) months) were assessed with [18F]dopa PET and UPDRS scoring on two occasions a mean of 18 (SD 6) months apart. PET data were sampled with separate caudate and putamen and total striatal regions of interest, and both graphical (Ki) and ratio methods of analysis. RESULTS: The mean annual rate of deterioration in [18F]dopa uptake varied according to structure and method of analysis, with putamen Ki showing the most rapid mean rate of progression (4.7% of normal mean per year). The group showed a significant deterioration (p<0.0004, paired two tailed t test) in UPDRS and in the putamen (p=0.008) and total striatal (p=0.012) [18F]dopa uptake measured using a graphical analysis, but no significant change in caudate or putamen uptake measured by a ratio approach. A study of sensitivity confirmed that putamen Ki was the most sensitive measure of disease progression, caudate ratio the least. Symptom onset in Parkinson's disease was estimated at a mean putamen [18F]dopa uptake (Ki) of 75% of normal and a mean caudate [18F]dopa uptake (Ki) of 91% of normal. CONCLUSIONS: Estimation of mean rate of progression varies according to the sensitivity of a functional imaging method to clinical severity. Sensitivity and reproducibility of method must be considered when designing studies of disease progression and neuroprotection. The mean preclinical period in Parkinson's disease is unlikely to be longer than seven years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
SCHEFFE, H. (1960) · Soil Science · doi:10.1097/00010694-196006000-00016 · Cited by 5,516
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Calculating correlation coefficients with repeated observations: Part 2—correlation between subjects
Bland, J. M., & Altman, D. G. (1995) · BMJ · doi:10.1136/bmj.310.6980.633 · Cited by 1,082
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease
Lees, A. J. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302969 · Cited by 491
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & William Langston, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
Cited by
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Self-citationSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationClinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Where Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
Association of olfactory dysfunction with risk for future Parkinson's disease
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J., Masaki, K., Launer, L., & White, L. R. (2008) · Annals of Neurology · doi:10.1002/ana.21291 · Cited by 742
Idiopathic hyposmia as a preclinical sign of Parkinson's disease
Ponsen, M. M., Stoffers, D., Booij, J., van Eck‐Smit, B. L. F., Wolters, E. C., & Berendse, H. W. (2004) · Annals of Neurology · doi:10.1002/ana.20160 · Cited by 740
Olfactory dysfunction in Parkinson disease
Doty, R. L. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.80 · Cited by 737
Braak, H., Bohl, J. R., Müller, C. M., Rüb, U., de Vos, R. A. I., & Del Tredici, K. (2006) · Movement Disorders · doi:10.1002/mds.21065 · Cited by 630
Contrasting acute and slow-growing lesions: a new door to brain plasticity
Desmurget, M., Bonnetblanc, F., & Duffau, H. (2006) · Brain · doi:10.1093/brain/awl300 · Cited by 515
Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study
Shiba, M., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<669::aid-mds1011>3.0.co;2-5 · Cited by 465
Medical records documentation of constipation preceding Parkinson disease: A case-control study
Savica, R., Carlin, J. M., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Bharucha, A. E., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34af5 · Cited by 430
Advances in markers of prodromal Parkinson disease
Postuma, R. B., & Berg, D. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.152 · Cited by 405
Changes in network activity with the progression of Parkinson's disease
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century
Claassen, D. O., Josephs, K. A., Ahlskog, J. E., Silber, M. H., Tippmann-Peikert, M., & Boeve, B. F. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7fac · Cited by 392
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder
Postuma, R. B., Lang, A. E., Massicotte-Marquez, J., & Montplaisir, J. (2006) · Neurology · doi:10.1212/01.wnl.0000203648.80727.5b · Cited by 392
The role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Self-citationGreffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354
Kleiner-Fisman, G., Fisman, D. N., Sime, E., Saint-Cyr, J. A., Lozano, A. M., & Lang, A. E. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.99.3.0489 · Cited by 351
Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A., & Montplaisir, J. Y. (2012) · Brain · doi:10.1093/brain/aws093 · Cited by 348
[ 123 I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., & Seibyl, J. (2001) · Neurology · doi:10.1212/wnl.57.11.2089 · Cited by 347
Limitations of current Parkinson's disease therapy
Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel-Courbon, C., & Montastruc, J.-L. (2003) · Annals of Neurology · doi:10.1002/ana.10513 · Cited by 337
Olfactory loss may be a first sign of idiopathic Parkinson's disease
Haehner, A., Hummel, T., Hummel, C., Sommer, U., Junghanns, S., & Reichmann, H. (2007) · Movement Disorders · doi:10.1002/mds.21413 · Cited by 333
When Does Parkinson Disease Start?
Savica, R., Rocca, W. A., & Ahlskog, J. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.135 · Cited by 312
Iranzo, A., Valldeoriola, F., Lomeña, F., Molinuevo, J. L., Serradell, M., Salamero, M., Cot, A., Ros, D., Pavía, J., Santamaria, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70152-1 · Cited by 311
Progression of Parkinson's disease in the clinical phase: potential markers
Maetzler, W., Liepelt, I., & Berg, D. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70291-1 · Cited by 305
Berendse, H. W., Booij, J., Francot, C. M. J. E., Bergmans, P. L. M., Hijman, R., Stoof, J. C., & Wolters, E. C. (2001) · Annals of Neurology · doi:10.1002/ana.1049 · Cited by 299
Cortical Lewy body pathology in the diagnosis of dementia
Harding, A. J., & Halliday, G. M. (2001) · Acta Neuropathologica · doi:10.1007/s004010100390 · Cited by 297
Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A. H., Rudolf, J., Herholz, K., & Heiss, W.-D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.378 · Cited by 293
Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study
O'Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira‐Moriyama, L., & Lees, A. J. (2008) · Movement Disorders · doi:10.1002/mds.21813 · Cited by 290
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 288
The Concept of Prodromal Parkinson’s Disease
Mahlknecht, P., Seppi, K., & Poewe, W. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150685 · Cited by 288
Treatment interventions for Parkinson's disease: an evidence based assessment
Rascol, O., Goetz, C., Koller, W., Poewe, W., & Sampaio, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08520-3 · Cited by 279
Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft
Hagell, P. (1999) · Brain · doi:10.1093/brain/122.6.1121 · Cited by 274
Progression of motor impairment and disability in Parkinson disease: A population-based study
Alves, G., Wentzel-Larsen, T., Aarsland, D., & Larsen, J. P. (2005) · Neurology · doi:10.1212/01.wnl.0000183359.50822.f2 · Cited by 271
Diagnosis and the premotor phase of Parkinson disease
Tolosa, E., Gaig, C., Santamaría, J., & Compta, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e318198db11 · Cited by 255
Head trauma preceding PD: A case-control study
Bower, J. H., Maraganore, D. M., Peterson, B. J., McDonnell, S. K., Ahlskog, J. E., & Rocca, W. A. (2003) · Neurology · doi:10.1212/01.wnl.0000068008.78394.2c · Cited by 205
Premotor Parkinson’s disease: Concepts and definitions
Siderowf, A., & Lang, A. E. (2012) · Movement Disorders · doi:10.1002/mds.24954 · Cited by 174
Huntington's disease progression
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H. A., Sahakian, B., Hodges, J. R., Rosser, A. E., Wood, N. W., & Brooks, D. J. (1999) · Brain · doi:10.1093/brain/122.12.2353 · Cited by 169
Self-citationCastro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., & Gama, M. J. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8295-4 · Cited by 156
“In PD, approximately 50–70% of the dopaminergic neurons are already lost at the time of clinical diagnosis [55].”
BackgroundProgression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
“The mean annual decline in putamen and caudate 18 F-dopa Ki noted in this study is comparable with data from previous studies (Morrish et al., 1996, 1998).”
BackgroundResultSelf-citationIn vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Self-citationAnemia or low hemoglobin levels preceding Parkinson disease: A case-control study
Savica, R., Grossardt, B. R., Carlin, J. M., Icen, M., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Steensma, D. P., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd80c1 · Cited by 87
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Jokinen, P., Helenius, H., Rauhala, E., Brück, A., Eskola, O., & Rinne, J. O. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.061572 · Cited by 72
Heng, N., Malek, N., Lawton, M. A., Nodehi, A., Pitz, V., Grosset, K. A., Ben‐Shlomo, Y., & Grosset, D. G. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13687 · Cited by 64
Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease
Di Folco, C., Couronné, R., Arnulf, I., Mangone, G., Leu‐Semenescu, S., Dodet, P., Vidailhet, M., Corvol, J., Lehéricy, S., & Durrleman, S. (2024) · Movement Disorders · doi:10.1002/mds.29662 · Cited by 16
(2002) · PubMed
Metadata
- Authors
- Morrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 1998-03-01
- Volume
- 64
- Issue
- 3
- Pages
- 314-319
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2156177559
- Cited by
- 510
- References
- 27
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.